Welcome to the iCAD Investors Page

Welcome to the iCAD Investors PageiCAD, Inc. an industry-leading provider of advanced image analysis, workflow solutions and radiation therapy for the early identification and treatment of cancer. The core business delivers innovative cancer detection and radiation therapy  solutions and services that enable clinicians to find and treat cancers earlier and  while enhancing patient care. The comprehensive iCAD technology platforms include advanced hardware and software as well as management services designed to support cancer detection (CAD) and radiation therapy (eBx) treatments.

The company's common stock is listed on the NASDAQ Stock Market under the symbol "ICAD".

iCAD Technology Innovation Day – Expanded ProFound AI Portfolio

Featuring presentations by Key Opinion Leaders Per Hall, MD, PhD (Karolinska Institutet), Axel Gräwingholt, MD (Radiologie am Theater), Joshua A. Nepute, MD (Indiana University Health-Arnett), and Emily F. Conant, MD (University of Pennsylvania Perelman School of Medicine) who will discuss the current landscape for digital breast tomosynthesis (DBT) and the potential for iCAD's recently introduced ProFound AI Risk, the first and only commercially available clinical decision support tool that provides an accurate two-year breast cancer risk estimation based solely on a screening mammogram.

iCAD Technology Innovation Day - Expanded ProFound AI Portfolio

iCAD Technology Innovation Day – Expanded Therapy Portfolio

Featuring presentations by Key Opinion Leaders (KOLs) Janie Grumley, MD, FACS (John Wayne Cancer Center), Té Vuong, MD, FRCP (McGill University & Jewish General Hospital), and Santosh Kesari, MD, PhD (John Wayne Cancer Center), who discuss the current treatment landscape and unmet medical need in treating patients with cancers such as breast, rectal, and glioblastoma multiforme. Also highlighted will be recently presented positive clinical data for Xoft® Brain IORT as viable treatment option for glioblastoma multiforme.

iCAD Technology Innovation Day – Expanded Therapy Portfolio

Quick Links

Corporate Profile

Events & Webcasts

Financial News/Events

Leadership

Reports & SEC Files

Stock Quote

Corporate Governance

Resources

Connect with iCAD

Educational Webinars

Investor Relations

LifeSci Advisors

Jeremy Feffer
917-749-1494

jeremy@lifesciadvisors.com

Media Inquiries

iCAD, Inc.
603.882.5200
pr@icadmed.com

Recycle - iCAD is committed to corporate sustainability and to making a difference for our environment.RoHS 2011 - iCAD is committed to corporate sustainability and to making a difference for our environment.China E - iCAD is committed to corporate sustainability and to making a difference for our environment.

iCAD is committed to corporate sustainability and to making a difference for our environment.

Recent Press Releases

Recent Events and Webcasts

© iCAD Inc.  All rights reserved.  iCAD, the iCAD logo, PowerLook, ProFound AI, ProFound, Xoft, the Xoft logo, Axxent, Electronic Brachytherapy System and eBx are trademarks of iCAD, Inc. Reproduction of any of the material contained herein in any format or media without the express written permission of iCAD, Inc. is prohibited.

Facebook icon Twitter icon LinkedIn icon

Welcome to the iCAD Investors PageiCAD, Inc. an industry-leading provider of advanced image analysis, workflow solutions and radiation therapy for the early identification and treatment of cancer. The core business delivers innovative cancer detection and radiation therapy  solutions and services that enable clinicians to find and treat cancers earlier and  while enhancing patient care. The comprehensive iCAD technology platforms include advanced hardware and software as well as management services designed to support cancer detection (CAD) and radiation therapy (eBx) treatments.

Welcome to the iCAD Investors Page